Five things for pharma marketers to know: Friday, August 23, 2019
Feds appeal overturned TV price-disclosure rule; Color Genomics picked to support federal genetic research initiative; Nonprofit tries to direct opioid settlements to hospitals.
Most recent articles by Alison Kanski
FDA, brands caught in the middle of CBD legalization
CBD, or cannabidiol, is a non-psychoactive compound in cannabis. Some claim it has health benefits from easing pain to controlling anxiety, and many Americans are already using it.
Five things for pharma marketers to know: Wednesday, August 21, 2019
Study: FDA anti-smoking campaign worked with teens; Allergan, Endo agree to settlement in Ohio opioid lawsuit; Executives depart Apple health team.
FDA says The Real Cost campaign stopped nearly 600,000 from smoking
Its research suggests the push could also help turn the tide against vaping.
How graphic warnings on cigarette packages stack up around the world
Many countries have implemented rules to make tobacco packaging much less appealing.
Five things for pharma marketers to know: Monday, August 19, 2019
Vaping group tries to delay FDA review of e-cigarettes; Roche genetic cancer treatment to cost less than competitor; Smile Direct Club files IPO.
Five things for pharma marketers to know: Friday, August 16, 2019
FDA proposes graphic warnings on cigarette packages; New York attorney general subpoenas Sackler financial documents; Planned Parenthood to withdraw from Title X program.
Our neighbor to the north wants nothing to do with U.S. drug prices
As U.S. leaders work to bring down soaring drug costs, Canada is distancing itself.
Outcome Health teams up with Verywell on content ‘wrapped in empathy’
Verywell will provide content for Outcome Health’s point-of-care devices.
